The Law Offices of Frank R. Cruz announces an investigation of BELLUS Health Inc. (“BELLUS” or the “Company”) (NASDAQ: BLU) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

BELLUS is a clinical-stage biopharmaceutical company whose lead product is BLU-5937, which is being developed for the treatment of chronic cough and other afferent hypersensitization-related disorders.

On July 6, 2020, before the market opened, BELLUS announced topline results from its Phase 2 RELIEF trial of BLUE-5937 in patients with refractory chronic cough. According to the Company, the trial “did not achieve statistical significance for the primary endpoint of reduction in placebo-adjusted cough frequency at any dose tested.”

On this news, the Company’s stock price fell $9.05, or 75%, over two consecutive trading sessions to close at $2.97 on July 8, 2020, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased BELLUS securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.